Other
Adult Subject
0
Pipeline Programs↗
29
Active Trials↗
137
Companies Involved↗
Adult Subject is an early-stage landscape with 0 programs across 137 companies. The most active players are GSK, Pfizer, Astellas.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
428
clinical trials
Completed357 · 83%
Unknown status19 · 4%
Terminated14 · 3%
Recruiting13 · 3%
Not yet recruiting10 · 2%
Withdrawn9 · 2%
Other6 · 1%
Clinical Trials
Trial Activity
428 trials
Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency
Recruiting·—·Phase 2·NCT06754098·15 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled
Page 1 of 29
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)